Back to top

FDA expands marketing of 23andMe to include medication metabolism

November 6, 2018
No votes yet


The FDA expanded the marketing of the 23andMe Personal Genome Service Pharmacogenetic Reports test to provide information about 33 genetic variants that may be linked with a patient’s ability to metabolize some medications to help inform discussions with a health care provider, according to an agency press release.